Skip to content
Donate
Membership
Contact
  • About

    About

    The peak professional body for childhood cancer across Australia and New Zealand.

    Learn More

    Menu

    • About ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Supporters & Partners
    • Position Statements & Guidelines
  • Clinical Trials
    Total Trials
    60
    Open Trials
    26
    Preparing to Open
    3
    Temp. Closed
    3
    Closed
    21
    Complete
    7

    Menu

    • Our Trials
    • Children's Clinical Cancer Clinical Trials Repository
    • Childhood Cancer
  • Resource SPACE
    Document/ PDF

    Supporting parents making clinical trial decisions for their child

    Behavioural Sciences Unit – Delta Study
    Document/ PDF

    Should my child participate in a clinical trial

    Center for Information and Study on Clinical Research Participation (CISCRP)

    Menu

    • Visit SPACE
    • Videos
    • Documents
    • Podcasts
  • Major Projects
    • July 2, 2025

    Getting to know CoACT in Brain Cancer Awareness Month

    • childhoodcancer, clinical trials, Paediatric Brain Cancer
    • February 6, 2025

    Australian Government invests $14 million in ANZCHOG-led childhood brain cancer initiative

    • childhoodcancer, clinical trials, Paediatric Brain Cancer

    Menu

    • CoACT
    • Equitable Pathways
    • CIRCCA
  • Annual Scientific Meeting

     Innovate, Integrate, Inspire:   Elevating Supportive Care in Paediatric Haematology and Oncology  

    Learn More

    Menu

    • 2026 Newcastle
    • Program
    • Speakers
    • Accommodation
  • News & Events
    • Featured, PaedNeoVax, Trial Update
    • November 5, 2026

    PaedNeoVax Clinical Trial Opens to Target Aggressive Childhood Brain Tumours

    Menu

    • Latest News
    • Upcoming Events
    • Featured, Fundraiser

    1–30 September 2027

    Run/walk/roll 90km during September (representing the ~90 Aussie kids diagnosed with cancer each month) - part of Childhood Cancer Awareness Month

    Better Challenge

  • About Us
    • ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Collaborators, Supporters & Partners
  • Clinical Trials
    • Clinical Trials
    • ANZCHOG Children’s Cancer Clinical Trials Repository
    • Childhood Cancer
  • Major Projects
    • CoACT
    • Equitable Pathways
    • CIRCAA
  • Resource Space
  • Membership
  • Annual Scientific Meeting
Membership
Donate
Contact
Closed to RecruitmentPhase 3

LINES

European Low and Intermediate Risk Neuroblastoma: A SIOPEN Study

View on registry →Registry IDs: NCT01728155

The treatment and prognosis (chance of cure) for a child with neuroblastoma is assessed by tests done at time of diagnosis. These tests include a biopsy of the tumour, special molecular tests on the tumour tissue, and investigations to determine whether the tumour has spread and if so, where. The results of all these tests are then used to decide the “stage” of the tumour (defined by its extent of spread) and the disease “risk” (the chance of disease recurrence).

This study is being done to establish the best treatment for children with neuroblastoma that has a low or intermediate risk of recurring. Different treatment will be given to children with low risk and intermediate risk disease and will vary depending on the tumour characteristics. This trial will determine which of the current treatments for low and intermediate risk neuroblastoma provides the best outcome.

The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation

Site Status
John Hunter Children's Hospital (NSW) Closed to Recruitment
Sydney Children's Hospital (NSW) Closed to Recruitment
Monash Children's Hospital (VIC) Closed to Recruitment
Royal Children's Hospital (VIC) Closed to Recruitment
Perth Children's Hospital (WA) Closed to Recruitment
Preparing to openOpenClosedComplete
Diagnosis StageNewly Diagnosed
Open Date31/05/2019
ConditionsNeuroblastoma
Patient Range90 Days – 18 years
05099+
Disease TypeNeuroblastoma and Ganglioneuroblastoma
Study TypeInterventional

Funders

ANZCHOG acknowledges the valuable support of LINES by:

Children's Cancer Foundation

Media & Publication Highlights

Last updated 7 November 2026

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

Great! We’ve received your information.

We couldn’t process your submission. Please retry

  • Terms Of Use
  • Privacy Policy
  • Terms Of Use
  • Privacy Policy
  • Resource Hub
  • Childhood Cancer
  • What We Do
  • Resource Hub
  • Childhood Cancer
  • What We Do
  • Our Trials
  • Our Network
  • Position Statements & Guidelines
  • Our Trials
  • Our Network
  • Position Statements & Guidelines

Email
info@anzchog.org

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

Copyright © 2026 ANZCHOG - All Rights Reserved

Linkedin-in